Abstract. Dauricine is the major bioactive component isolated from the roots of Menispermum dauricum D.C. The aim of the present study was to investigate the role of P-glycoprotein in the transport of dauricine across the blood-brain barrier by pre-treatment with the P-glycoprotein inhibitor verapamil. Sprague Dawley rats were divided into a verapamil group (pretreated with verapamil at a dose of 20 mg/kg) and a control group (pretreated with the same volume of normal saline). After 90 min, the animals were injected intravenously with dauricine (10 mg/kg). At 15, 30 and 60 min after dauricine administration, the levels of dauricine in the blood and brain were detected by high-performance liquid chromatography. Compared with the control group, the dauricine concentration in the brains of the rats in the verapamil group was significantly increased. Furthermore, the brain-plasma ratio of dauricine in the rats pretreated with verapamil was significantly higher than that of the animals in the control group. However, there was no difference identified between dauricine levels in the plasma of the verapamil and the control groups. The results indicated that dauricine is able to pass the blood-brain barrier, and that P-glycoprotein has an important role in the transportation of dauricine across the blood-brain barrier.
Introduction
The blood-brain barrier (BBB) is a diffusion barrier essential for the normal function of the central nervous system (CNS). The BBB has a key role in maintaining homeostasis within the CNS, preserving the composition of the internal milieu, despite variations in the periphery, and protecting the brain against toxins, bacteria and viruses. Moreover, it regulates the uptake of endogenous molecules and xenobiotics into the brain (1) . Drug delivery to the CNS is one of the major hurdles in the development of novel therapeutics for neuropsychiatric disorders. In particular, there is a requirement for transport across the BBB, which separates the circulating blood from the CNS, for centrally acting drugs to achieve therapeutic concentrations at their site of action. Of note, >98% of potential CNS drugs are unable to cross the BBB to reach target sites within the brain (2) . The BBB is the bottleneck in brain drug development and is the single most important factor limiting future development of neurotherapeutics (3) .
P-glycoprotein is a plasma membrane glycoprotein that is able to exclude a wide range of chemotherapeutic drugs and other hydrophobic compounds from cells (4) . It is also expressed at high levels in non-cancerous tissues, such as the endothelial cells of BBB capillaries in humans, as well as animals. P-glycoprotein may be involved in the exclusion of various drugs from the capillary endothelial cells, blocking their entry into the brain (5) . Verapamil is the most extensively characterized P-gp inhibitor and multidrug resistance-associated protein (MDR) reversal agent (6) .
Dauricine ( Fig. 1 ) is a bisbenzylisoquinoline alkaloid isolated from the root of Menispermum dauricum D.C. Dauricine has been suggested for the treatment of various diseases, including cardiac ischemia, angina and inflammation (7, 8) . Previous studies have demonstrated that dauricine inhibits angiogenesis in tumors (9) and promotes apoptosis in tumor cells (10) . A study by Li and Gong (11) suggested that dauricine exhibits neuroprotective action in rats subjected to transient focal cerebral ischemia by attenuating apoptosis in the ischemic penumbra (12) . However, it has yet to be elucidated whether dauricine is capable of crossing the BBB. The main purpose of the present study was thus to investigate whether dauricine is able to cross the BBB by assessing dauricine levels in the plasma and brain tissue of rats. The rats were kept with free access to food and water and a 12 h light/dark cycle. They were housed in plastic cages and randomly divided into two groups: The control and verapamil groups, containing 24 animals each. The rats in the verapamil group were administered intraperitoneally (i.p.) with verapamil at a dose of 20 mg/ kg. The rats in the control group were treated with an equal volume of normal saline. After 90 min, all rats were injected with dauricine (15 mg/kg) through the tail vein. At 15, 30 and 60 min after dauricine treatment, the animals were anesthetized with chloral hydrate (300 mg/kg, i.p.) and then 5 ml heparinized blood [add 100 µl of 1% heparin (Tianjin Biochem Pharmaceutical Company, Tianjin, China ) into the blood] was collected from the abdominal aorta. The blood samples were centrifuged (3,500 x g, 4˚C) for 10 min and the plasma was separated. A 600-µl aliquot of plasma was added to 1,200 µl methanol. Subsequent to vortexing, 3 ml dichloromethane was added, and the mixture was vortexed for 3 min and centrifuged at 3,500 x g for 10 min. The organic layer was removed and evaporated to dryness at 40˚C under a stream of nitrogen.
Materials and methods

Drugs
The residue was dissolved in 600 µl mobile phase, and 10 µl supernatant liquid was injected into the HPLC system. The rats were perfused with 100 ml ice-cold normal saline each. The brain was instantly removed from the cranium and weighed. The brain was then homogenized in four aliquots of 0.1 mol/l ice-cold phosphate buffer (pH 7.4). Dichloromethane (3 ml) was added to 600 µl homogenate. Following vortexing for 3 min and centrifuging (3,500 x g, 4˚C) for 10 min, the supernatants were evaporated to dryness under a stream of nitrogen at 40˚C. The residue was analyzed according to the method outlined in the proceeding section.
Chromatographic conditions. The chromatographic separation was performed using an Agilent 1260 Series HPLC system (Agilent Technologies, Santa Clara, CA, USA). The HPLC system consisted of a quaternary pump, an ultraviolet detector operated at 281 nm and a Diamonsil C18 column (250x4.6 mm, 5 µm) protected with a guard column packed with the same material. The column was kept at room temperature. The mobile phase was acetonitrile-0.4% phosphate buffer (20:80, v/v). The pump was operated at a flow rate of 1 ml/min.
Statistical analysis.
Data are expressed as the mean ± standard deviation. The statistical significances of the data were determined using one-way analysis of variance followed by Least Significant Difference testing. P<0.05 was considered to indicate a statistically significant difference. Fig. 3 shows typical HPLC chromatograms of the brains of untreated rats, brain spiked with dauricine (standard) and tetrandrine (internal standard, No. 110711; National Institutes for Food and Drug Control, Beijing, China), and brain of rats treated with dauricine and spiked with tetrandrine (internal standard). Fig. 4 shows typical HPLC chromatograms of plasma from untreated rats, plasma spiked with dauricine and tetrandrine, and plasma of rats treated with dauricine and spiked with tetrandrine. The retention times of dauricine and tetrandrine were 5.3 and 12.8 min, respectively, where tetrandrine was the internal standard.
Results
HPLC of dauricine.
Effect of verapamil on the dauricine concentration in the brain.
At 15, 30 and 60 min after dauricine treatment, dauricine levels in the brain of the verapamil group was significantly increased compared with those of the control group (P<0.01, Fig. 5 ).
Effect of verapamil on dauricine levels in plasma.
Compared with the control, pretreatment with verapamil exerted no significant effect on dauricine levels in plasma (Fig. 6) . Effect of verapamil on the dauricine brain:plasma ratio. At 15, 30 and 60 min after dauricine treatment, the dauricine brain:plasma ratio in the verapamil group was significantly wincreased compared with that of the control group (P<0.01, Fig. 7 ).
Discussion
The BBB, which is situated between the blood and the brain tissue, regulates the entry of drugs into the brain. The therapeutic effect or the toxicity of drugs to the CNS is dependent on the integrity of the BBB. The barrier function of the BBB originates from two major aspects: Firstly, the physiological structure, comprising brain microvessel endothelial cells, astrocytes and tight junctions between the endothelial cells, is the basis of the barrier function (12) . Secondly, various types of transport proteins (13) at the BBB mediate the adsorption, excretion, distribution and elimination of drugs.
The results of this study demonstrated that at 15 min after dauricine administration, dauricine concentration in the brain reached a high level in the control and verapamil groups, which indicated that dauricine is able to cross the BBB. Furthermore, dauricine levels in the brain of the verapamil group were significantly higher than those in the control; however, verapamil did not affect dauricine levels in plasma, which suggested that the effect of verapamil on dauricine levels in the brain did not depend on the interference with the elimination of dauricine from the blood. In turn, it may be deduced that P-glycoprotein has an important role in the elimination of dauricine from the brain, as verapamil, an inhibitor of P-glycoprotein, was capable of increasing the levels of dauricine in the brain.
This study only evaluated the influence of P-glycoprotein on the levels of dauricine, and the effect of dauricine on P-glycoprotein expression was not taken into consideration. As a result, further studies are required to focus on whether dauricine is able to modulate the function or expression of P-glycoprotein.
In conclusion, the present study demonstrated that dauricine is able to pass the BBB. It was also shown that inhibiting P-glycoprotein was able to enhance dauricine levels in the brain. The results suggest that dauricine, originating from Traditional Chinese Medicine, may be a promising candidate for the treatment of CNS disorders.
